300639.SZ SHZ
Guangdong Hybribio Biotech Co.,Ltd.
1W: +2.4%
1M: +6.8%
3M: +21.8%
YTD: -13.8%
1Y: -6.1%
3Y: -42.1%
5Y: -50.8%
¥6.32 ($0.94)
+0.12 (+1.94%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$816M
-26.2% ▼
5Y CAGR: +2.3%
Gross Profit
$389M
-42.3% ▼
5Y CAGR: -7.9%
Operating Income
-$822M
-2028.9% ▼
Net Income
-$655M
-566.2% ▼
EPS (Diluted)
$-1.02
-508.0% ▼
EBITDA
-$662M
-382.6% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $1.4B | $2.7B | $5.6B | $1.1B | $816M |
| YoY Growth | +85.7% | +97.3% | +109.4% | -80.3% | -26.2% |
| Cost of Revenue | $361M | $865M | $1.7B | $430M | $427M |
| Gross Profit | $994M | $1.8B | $3.9B | $674M | $389M |
| Gross Margin | 73.4% | 67.6% | 69.4% | 61.0% | 47.7% |
| R&D Expenses | $72M | $115M | $247M | $118M | $86M |
| SG&A Expenses | $380M | $471M | $603M | $368M | $243M |
| Operating Expenses | $518M | $701M | $1.1B | $631M | $1.2B |
| Operating Income | $469M | $1.1B | $2.2B | $43M | -$822M |
| Operating Margin | 34.6% | 40.2% | 39.2% | 3.9% | -100.8% |
| Interest Expense | $801K | $7M | $10M | $6M | $2M |
| Income Before Tax | $464M | $1.1B | $2.1B | $38M | -$833M |
| Tax Expense | $69M | $172M | $326M | -$32M | $117M |
| Net Income | $363M | $852M | $1.7B | $140M | -$655M |
| Net Margin | 26.8% | 31.9% | 30.8% | 12.7% | -80.3% |
| EPS (Diluted) | $0.59 | $1.30 | $2.65 | $0.25 | $-1.02 |
| EBITDA | $515M | $1.2B | $2.3B | $234M | -$662M |
| Shares Outstanding | 614M | 655M | 652M | 562M | 642M |